Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego – wielospecjalistyczna jednostka opieki zdrowotnej, mieszcząca się przy ul. Borowskiej 213 we Wrocławiu. Organem założycielskim jest Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu.

During the past decade, Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu conducted 137 clinical trials. In the 10-year time frame, 137 clinical trials started and 60 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 80 clinical trials started and 42 clinical trials were completed. i.e. 52.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu" #1 sponsor was "Janssen Research & Development, LLC" with 21 trials, followed by "Pfizer" with 21 trials sponsored, "Celgene" with 19 trials sponsored, "Hoffmann-La Roche" with 13 trials sponsored and "Takeda" with 13 trials sponsored. Other sponsors include 88 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "National Center for Research and Development, Poland" with 2 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu" are "Multiple Myeloma" (9 trials), "Crohn Disease" (7 trials), "Chronic Lymphocytic Leukemia" (5 trials), "Myelodysplastic Syndromes" (5 trials) and "Diffuse Large B-cell Lymphoma" (4 trials). Many other conditions were trialed in "Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu" in a lesser frequency.

Most popular intervention types in "Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu" are "Drug" (150 trials), "Biological" (24 trials), "Other" (22 trials), "Device" (3 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (37 trials), "Rituximab" (11 trials), "Lenalidomide" (9 trials), "Dexamethasone" (7 trials) and "Azacitidine" (5 trials). Other intervention names were less common.

The vast majority of trials in "Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu" are 168 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 85 active trials in "Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu". 1 are not yet recruiting, 58 are recruiting, 24 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 72 completed trials in Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, 11 "Phase 1" clinical trials were conducted, 50 "Phase 2" clinical trials and 104 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 3 trials that are defined as “Not Applicable".